Alzheimer's disease (AD) is a serious public health problem, with a significant socioeconomic impact. The global cost associated with dementia reaches 154 billion euros per year, only in Western Europe. Early detection of AD, in its phase of mild cognitive impairment (MCI), is essential to optimize treatment. However, the diagnosis of MCI and AD requires a complex study. The fundamental objective of this project is to design a tool based on the analysis of the complete genome (through oral mucosa samples) and brain activity (using the electroencephalogram, EEG), which simplifies the current diagnostic protocols.